Scheduling Chemotherapy: Catch 22 between Cell Kill and Resistance Evolution
From MaRDI portal
Publication:4489320
Recommendations
- Evolution of resistance to anti-cancer therapy during general dosing schedules
- Conflicting objectives in chemotherapy with drug resistance
- scientific article; zbMATH DE number 819191
- scientific article; zbMATH DE number 1448576
- scientific article; zbMATH DE number 1114142
- Drug resistance in cancer chemotherapy as an optimal control problem
- Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies
- Chemotherapeutic Treatments with Time Increasing Mutation Rate to Drug Resistance
- Optimization of an \textit{in vitro} chemotherapy to avoid resistant tumours
Cited in
(9)- The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics
- scientific article; zbMATH DE number 2015390 (Why is no real title available?)
- The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling
- Evolution of resistance to anti-cancer therapy during general dosing schedules
- Dynamics of breast cancer under different rates of chemoradiotherapy
- scientific article; zbMATH DE number 819191 (Why is no real title available?)
- Second-Order Effects of Chemotherapy Pharmacodynamics and Pharmacokinetics on Tumor Regression and Cachexia
- Cell resensitization after delivery of a cycle-specific anticancer drug and effect of dose splitting: learning from tumour cords
- Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs
This page was built for publication: Scheduling Chemotherapy: Catch 22 between Cell Kill and Resistance Evolution
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4489320)
